Join our global community

Join over 50,000+ people in the Psychedelic Finance community. Our free newsletter helps investors discover, understand and stay up to date with the business of psychedelics.

Compass Pathways initiates UK component of global phase 3 study of psilocybin treatment in treatment-resistant depression and launches new research center

November 15, 2023

November 16, 2023

Cybin Announces Closing of Offering of Units Led by One of the Company’s Largest Institutional Shareholders

September 7, 2023

Optimi Health Granted Amendment to Dealer's Licence by Health Canada to Supply Special Access Program

Latest News

November 16, 2023

Cybin Announces Closing of Offering of Units Led by One of the Company’s Largest Institutional Shareholders

November 15, 2023

Compass Pathways initiates UK component of global phase 3 study of psilocybin treatment in treatment-resistant depression and launches new research center

November 9, 2023

Clearmind Medicine to Pioneer Psychedelic Clinical Trials for Alcohol Use Disorder with Ivy League Universities

November 1, 2023

Cybin's CYB003 Demonstrates Remarkable Interim Data in Treating Major Depressive Disorder

October 25, 2023

Cybin Announces Grant of Two New United States Patents Protecting its Deuterated DMT Program

October 24, 2023

Cybin Announces Grant of European Patent Protecting its Proprietary Deuterated Programs

October 23, 2023

Cybin Completes Acquisition of Small Pharma Inc. to Create International Clinical-stage Leader in Novel Psychedelic Therapeutics

September 26, 2023

Cybin Announces Agreement with Fluence to Support Scaling of EMBARK Training for CYB003 Phase 3 Trial

September 8, 2023

COMPASS Pathways announces publication of first study evaluating potential of AI model to predict outcomes of COMP360 psilocybin treatment in treatment-resistant depression

September 7, 2023

Optimi Health Granted Amendment to Dealer's Licence by Health Canada to Supply Special Access Program

September 6, 2023

Clearmind Medicine Announces Clinical Research Collaboration with Johns Hopkins University to Evaluate CMND-100 in Patients with Alcohol Use Disorder

September 6, 2023

Awakn Life Sciences Submits Clinical Trial Application for Phase III Trial of AWKN-P001

August 31, 2023

Otsuka Pharmaceutical to Acquire Mindset Pharma

August 30, 2023

Nova Mentis Announces Participant Screening Underway in Canada's First Psilocybin Clinical Trial for Fragile X Syndrome

August 28, 2023

Cybin to Acquire Small Pharma Inc.

August 16, 2023

COMPASS Pathways Announces Up to $285 Million Private Placement Financing Joined by Leading Healthcare Investors

August 15, 2023

Cybin Announces Grant of U.S. Patent Covering Proprietary Deuterated Psilocybin Analog in its CYB003 Program

Filament Health Announces Fda Approval Of Two Clinical Trials Studying Its Botanical Psilocybin Drug Candidate Pex010

Algernon NeuroScience Announces 40 Patient Phase 2 Psychedelic Drug DMT Stroke Study

Cybin Initiates Dosing of Final Cohort of its Phase 2 Trial of CYB003 in Major Depressive Disorder

Spotlights

Explore our collection of exclusive interviews featuring visionary scientists, leaders, and executives who are propelling the industry forward with their innovative ideas and groundbreaking work.

View All Spotlights

View All Spotlights

Get the Headlines & Market Updates

Be the first to see new company features, exclusive interviews and breaking news. Subscribe now.

Home News Companies Spotlights Subscribe

©XXXX Psychedelic Finance. All rights reserved.

Core One Labs Inc.

Enveric Biosciences

Field Trip Health

Filament Health

Mydecine Innovations Group

NeonMind Biosciences Inc.

PsyBio Therapeutics

Psyched Wellness

Pure Extracts Corp

The Good Shroom Co

Tryp Therapeutics

Algernon Pharmaceuticals

Beckley Foundation

BetterLife Pharma

Bexson Biomedical

Braxia Scientific Corp.

CB Therapeutics

Ceruvia Lifesciences

Clairvoyant Therapeutics

Clearmind Medicine

Clexio Biosciences

Cognetivity Neurosciences

Delix Therapeutics

Diamond Therapeutics

Freedom to Operate

HMNC Brain Health

Horizons ETFs Management Inc.

Incannex Healthcare

Ixtlan Bioscience

Johns Hopkins Medicine

MYND Diagnostics

Mind Medicine (MindMed)

MindBio Therapeutics

Mycotopia Therapies

Mycrodose Therapeutics

Neural Therapeutics

Nirvana Life Sciences

Nova Mentis Life Science

Origin Therapeutics

Pasithea Therapeutics

Pharmala Biotech Holdings

Psilotec Health Solutions

Quantified Citizen

Reunion Neuroscience

Revitalist Lifestyle and Wellness

Revive Therapeutics

Seelos Therapeutics

Telescope Innovations

Universal Ibogaine

Wellbeing Digital Sciences

Woke Pharmaceuticals

ATAI Life Sciences

Awakn Life Sciences

Beckley Psytech

Compass Pathways

Doseology Sciences

Entheon Biomedical

Gilgamesh Pharmaceuticals

GoodCap Wellness